Navigation Links
FDA Panel Recommends Testing of Electroshock Devices
Date:1/31/2011

SATURDAY, Jan. 29 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration decided on Friday that electroconvulsive (also known as "electroshock") devices should be subject to the same tough testing as other medical devices entering the market.

The much-awaited decision is the latest chapter in the decades-old controversy surrounding the psychiatric treatment, which some patients see as doing great harm, even as others hail it as a valuable treatment.

The FDA doesn't have to follow its advisory committees' recommendations but usually does.

The panel's decision was endorsed by those worried about the potential harms of electroconvulsive therapy (ECT).

"It was the best possible outcome we could have gotten," Austin, Texas-based clinical psychologist John Breeding told the Washington Post. Breeding, a longtime opponent of the procedure, testified before the panel at a two-day meeting that began Thursday in Gaithersburg, Md.

The panel heard testimony from both ECT patients and FDA researchers who pored over hundreds of studies into the therapy. According to the Post, the FDA staffers said that current research suggests ECT does outperform placebo or "sham" ECT and after a month it may also outperform antidepressants.

But on the other hand, the FDA review of data also found that the treatment was tied to "impairment in orientation, memory and global cognitive function immediately after ECT and up to six months," the Post reported, although many aspects of memory do seem to return to normal after another six months.

Supporters of electroshock had lobbied for the devices to be downgraded to a medium-risk classification, which would put the devices in the same category as syringes and allow them to be sold without new testing.

The advisory panel did not support such a move, and their recommendation might push the FDA to require manufacturers to demonstrat
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Panel Recommends Tougher Standards for External Defibrillators
2. AADR testifies to the FDA advisory panel on dental amalgam
3. FDA Panel Calls for Safety Review of Mercury in Dental Fillings
4. New Diet Pill Wins FDA Panels Backing
5. NIH-sponsored panel issues comprehensive US food allergy guidelines
6. Expert panel addresses safety in medical imaging
7. FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer
8. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
9. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
10. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
11. Teens Should Get Meningitis Booster Shot: CDC Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Global Health Innovative Technology Fund (GHIT Fund), a ... know-how and investment to the global fight against ... US$15.3 million to speed the development of promising ... dengue and Chagas disease. The announcement marks the ... November 2013totaling $33.5 millionaimed at diseases that sicken ...
(Date:9/15/2014)... September 15, 2014 Ondine Biomedical ... Loebel, its President and Chief Technology Officer, will ... Photodynamic Therapy (PDT) and Photodiagnosis in Clinical Practice. ... Brixen/Bressanone (Italy) from October 14-18, 2014 alongside the ... on October 13-14th, is an annual conference at ...
(Date:9/15/2014)... VA (PRWEB) September 15, 2014 ... and management consulting services to the federal government, ... in Alexandria, Virginia and Atlanta, Georgia to better ... catalyst for this expansion is credited to the ... in the core areas of management consulting, agile ...
(Date:9/15/2014)... out of every 40 individuals in the United States is ... (SMA), a neurodegenerative disease that causes muscles to weaken over ... a recent breakthrough with the development of a new compound ... disease. In April, a patent was filed for the compound ... using to fight SMA is to ,repress the repressor," said ...
(Date:9/15/2014)... In order to provide predictability and safety, the ... quantify, define and model medical practice. Defined as Bioinformatics ... medical care. , The Journal of BioAcoustic Biology ( ... non-profit Institute of BioAcoustic Biology, located in Albany, Ohio, ... much more than a measurement tool; math, as frequency, ...
Breaking Medicine News(10 mins):Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 4Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 5Health News:Ondine Presenting at the 2014 International Symposium on Photodynamic Therapy and Photodiagnosis 2Health News:Octo Consulting Group Announces it is Opening Two New Offices in Alexandria, Virginia and Atlanta, Georgia to Better Serve Existing and Future Federal Government Clients 2Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3
... survival rate of non-small-cell lung cancer patients after ... Cisplatin is an anti-neoplastic medication that interferes with ... growth and spread in the body. ... three or four cycles of cisplatin-based chemotherapy or ...
... the world's first epilepsy drug, an Australian neurologist says.// ... a mild sedative, taken either as a herbal infusion ... form. ,But the Italian author Fabio Colonna first ... botanical work Phytobasanos. ,Colonna said he had controlled ...
... around 700,000 people researchers say dads who have children ... // for developing schizophrenia later in life. ... to the hospital in Sweden between 1989 and 2001 ... Researchers say they found a strong association between the ...
... recent study shows that people who use stomach-acid suppressive ... may be at an increased risk of developing pneumonia ... the stomach can increase vulnerability to infections, as stomach ... Researchers studied pneumonia rates of more than 364,000 patients ...
... study researchers say they have found that the drug ... cancer // decreased patients' cancer incidence after 12 months ... some impact, but the 20-milligram dose had the greatest ... prostatic intraepithelial neoplasia, characterized by abnormal cells in the ...
... New research shows that sleep disorders may be linked ... ADD ), // neuromuscular conditions, and psychiatric problems. ... patients with sleep apnea also had ADD. Results also ... insomnia. Further testing showed some of these patients also ...
Cached Medicine News:Health News:Valerian was first epilepsy drug 2
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- Asthma ... persons of all ages, but most commonly starts ... characterized by narrowing of the airways, leading to ... lungs come into contact with endogenous and exogenous ... events, such as swelling of the airways, tightening ...
(Date:9/15/2014)... MedicOne Medical Response, a leading provider emergency and ... Inc. Magazine as one of the fastest growing ... - http://photos.prnewswire.com/prnh/20140914/145997 The ... with the largest revenue growth between 2010 and ... ambulance companies to make the list, achieved an ...
(Date:9/15/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... 2014, regular quarterly dividend payment of $0.15 per share ... September 5, 2014, the record date. About ... of patents and royalty assets, consisting primarily of its ... with various biotechnology and pharmaceutical companies. PDL pioneered the  ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... 11, 2011 Vanda Pharmaceuticals Inc. (NASDAQ: ... Corporation, an affiliate of Vanda,s sublicensor Novartis Pharma ... the long-acting injectable (or depot) formulation of Fanapt® ... will evaluate the safety and pharmacokinetic profiles of ...
... 11, 2011 Merck (NYSE: MRK ), ... and Intercell AG (VSE: ICLL) today announced that following ... trial evaluating V710, an investigational vaccine for the prevention ... Monitoring Committee (DMC) recommended suspension of enrollment. Although the ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 2Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 3
...
...
... exercise BP monitor is designed to automatically ... diastolic BP along with heart rate. It's ... use in treadmill, ergometer and pharmacological stress ... use in research environments., ,Tango excels ...
...
Medicine Products: